Sabre Corporation's subsidiary Sabre Financial Borrower, LLC has started a tender offer to buy back up to $1 billion of its 11.125% Senior Secured Notes due 2029. The offer includes an early tender premium and requires holders to consent to amendments that remove most restrictive covenants and certain default events. The tender offer expires on October 12, 2026, with an early tender deadline of September 25, 2026. Sabre plans to fund the buyback through a new $1.1 billion senior secured notes offering due 2032, but completion depends on financing and other conditions. This move aims to restructure debt terms and improve financial flexibility.
Sabre Corporation's debt tender offer is the subject of this update, with Pluang's Financials sector showing mixed activity. For readers following Financials, here is Pluang's market snapshot as of Sep 14, 2026 19:01 WIB: of 74 priced US stocks, 33 rose and 28 fell. Notable price changes include Affirm Holdings Inc (AFRM) up 2.16% to USD 72.98, Banco Santander SA (SAN) down 2.14% to USD 14.64, and SoFi Technologies Inc (SOFI) down 1.96% to USD 16.98.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
